We are live on ! Find out more
TMO icon

Thermo Fisher Scientific

2,031 hedge funds and large institutions have $164B invested in Thermo Fisher Scientific in 2020 Q4 according to their latest regulatory filings, with 276 funds opening new positions, 751 increasing their positions, 739 reducing their positions, and 70 closing their positions.

New
Increased
Maintained
Reduced
Closed

294% more first-time investments, than exits

New positions opened: 276 | Existing positions closed: 70

10% more funds holding

Funds holding: 1,8472,031 (+184)

5% more capital invested

Capital invested by funds: $156B → $164B (+$8.53B)

2% more repeat investments, than reductions

Existing positions increased: 751 | Existing positions reduced: 739

0.99% less ownership

Funds ownership: 89.16%88.17% (-0.99%)

7% less funds holding in top 10

Funds holding in top 10: 198184 (-14)

19% less call options, than puts

Call options by funds: $976M | Put options by funds: $1.21B

Holders
2,031
Holders Change
+184
Holders Change %
+9.96%
% of All Funds
35.93%
Holding in Top 10
184
Holding in Top 10 Change
-14
Holding in Top 10 Change %
-7.07%
% of All Funds
3.26%
New
276
Increased
751
Reduced
739
Closed
70
Calls
$976M
Puts
$1.21B
Net Calls
-$229M
Net Calls Change
-$95M
Name Holding Trade Value Shares
Change
Change in
Stake
MMPW
1351
Mitchell McLeod Pugh & Williams
Alabama
$740K
SCM
1352
Spreng Capital Management
Ohio
$738K -$142K -302 -16%
BHB
1353
Bank Hapoalim BM
Israel
$738K +$120K +255 +19%
EMG
1354
ETF Managers Group
New Jersey
$736K -$914K -1,950 -55%
AWA
1355
ARS Wealth Advisors
Florida
$736K +$16.4K +35 +2%
SWM
1356
SeaCrest Wealth Management
New York
$732K -$51.1K -109 -6%
ESB
1357
Essex Savings Bank
Connecticut
$726K -$296K -632 -29%
CHP
1358
Cable Hill Partners
Oregon
$724K -$37.5K -80 -5%
MA
1359
Mutual Advisors
Nebraska
$721K +$20.2K +43 +3%
HPC
1360
Hobart Private Capital
North Carolina
$720K +$53K +113 +8%
CC
1361
Chicago Capital
Illinois
$719K +$317K +676 +78%
AWM
1362
Apollon Wealth Management
South Carolina
$717K -$249K -531 -26%
Fayez Sarofim & Co
1363
Fayez Sarofim & Co
Texas
$714K +$70.3K +150 +11%
AssetMark Inc
1364
AssetMark Inc
California
$711K -$88.6K -189 -11%
FNFDCM
1365
Folger Nolan Fleming Douglas Capital Management
District of Columbia
$708K +$23.4K +50 +3%
TP
1366
Tranquility Partners
Tennessee
$707K
EH
1367
Equitable Holdings
New York
$707K +$15.5K +33 +2%
OFS
1368
Oldfather Financial Services
Nebraska
$706K
1W
1369
1776 Wealth
Georgia
$705K +$8.44K +18 +1%
BOPW
1370
Brandywine Oak Private Wealth
Pennsylvania
$704K -$1.88K -4 -0.3%
TCM
1371
Tributary Capital Management
Nebraska
$701K -$164K -350 -19%
CPO
1372
Cerity Partners OCIO
New York
$699K +$22K +47 +3%
CCIA
1373
Campbell & Co Investment Adviser
Maryland
$699K +$703K +1,500 New
SRSA
1374
S.R. Schill & Associates
Washington
$693K +$203K +432 +41%
AIC
1375
Archer Investment Corporation
Indiana
$687K +$14.1K +30 +2%

TMO Hedge Fund Activity: Q4 2020 in Review

2,031 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Thermo Fisher Scientific (TMO) for Q4 2020, worth a combined $164B — up 5.5% from $156B a quarter earlier.

Buyers outnumbered sellers: 276 funds opened new TMO positions and 70 closed out — a net gain of 206 holders — while 751 added to existing stakes and 739 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $322M. The largest seller was Capital Research Global Investors, cutting an estimated $770M.

  • 2,031 institutional investors held Thermo Fisher Scientific (TMO) as of Q4 2020, up from 1,847 in Q3 2020.
  • Funds reported $164B of Thermo Fisher Scientific stock for Q4 2020, up 5.5% quarter-over-quarter.
  • 276 funds opened new Thermo Fisher Scientific positions in Q4 2020 and 70 closed out, a net change of +206 holders.
  • The largest Thermo Fisher Scientific buyer in Q4 2020 was Fidelity Investments, an estimated $322M added.
  • The largest Thermo Fisher Scientific seller in Q4 2020 was Capital Research Global Investors, an estimated $770M sold.

Based on aggregated 13F filings for Q4 2020.